Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials
Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent paper by him as co-author, titled “Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types” published on The Lancet.
Authors: Karl Semaana, Rashad Nawfala, Elizabeth Nally, Yelena Y Janjigianc, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri
“Excited to share our work on the landscape of subsequent therapies in perioperative IO trials across cancer types. Effort co-led with Karl Semaan with great mentorship from Solange Peters, Tom Powles, Toni Choueiri.
We examined the landscape of subsequent therapies in perioperative immunotherapy trials, revealing key trends and unmet needs in adjuvant trials for melanoma, NSCLC, Gastroesophageal junction adenocarcinoma, UC, and RCC.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023